# Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

> **NCT02950051** · PHASE3 · COMPLETED · sponsor: **German CLL Study Group** · enrollment: 926 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Venetoclax
- **BIOLOGICAL:** Obinutuzumab
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02950051
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-13
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 926 (ACTUAL)
- **Last updated:** 2024-12-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02950051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02950051, "Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02950051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*